Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1982 3
1983 9
1984 12
1985 11
1986 18
1987 31
1988 42
1989 65
1990 66
1991 61
1992 57
1993 64
1994 76
1995 49
1996 71
1997 50
1998 56
1999 55
2000 70
2001 59
2002 75
2003 64
2004 44
2005 66
2006 61
2007 68
2008 64
2009 73
2010 62
2011 60
2012 62
2013 77
2014 53
2015 69
2016 51
2017 37
2018 45
2019 45
2020 39
2021 38
2022 38
2023 41
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

2,029 results

Results by year

Filters applied: . Clear all
Page 1
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS; POEMS/S0230 Investigators. Moore HC, et al. N Engl J Med. 2015 Mar 5;372(10):923-32. doi: 10.1056/NEJMoa1413204. N Engl J Med. 2015. PMID: 25738668 Free PMC article. Clinical Trial.
METHODS: We randomly assigned 257 premenopausal women with operable hormone-receptor-negative breast cancer to receive standard chemotherapy with the GnRH agonist goserelin (goserelin group) or standard chemotherapy without goserelin (chemotherapy-alone group …
METHODS: We randomly assigned 257 premenopausal women with operable hormone-receptor-negative breast cancer to receive standard chemotherapy …
Goserelin ('Zoladex')--offering patients more choice in early breast cancer.
Mitchell H. Mitchell H. Eur J Oncol Nurs. 2004;8 Suppl 2:S95-103. doi: 10.1016/j.ejon.2004.09.004. Eur J Oncol Nurs. 2004. PMID: 15590321 Review.
The luteinising hormone-releasing hormone analogue goserelin ('Zoladex') suppresses ovarian oestrogen production in pre- and perimenopausal women. Goserelin is a biodegradable, sustained-release 3.6 mg depot that is administered by subcutaneous injection every 28 da …
The luteinising hormone-releasing hormone analogue goserelin ('Zoladex') suppresses ovarian oestrogen production in pre- and perimeno …
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders.
Perry CM, Brogden RN. Perry CM, et al. Drugs. 1996 Feb;51(2):319-46. doi: 10.2165/00003495-199651020-00009. Drugs. 1996. PMID: 8808170 Review.
Randomised clinical comparisons of depot goserelin with danazol indicate that goserelin is at least as effective as danazol and is better tolerated in the treatment of endometriosis. ...Goserelin is also an effective alternative to surgery in this patient gro …
Randomised clinical comparisons of depot goserelin with danazol indicate that goserelin is at least as effective as danazol an …
Clinical pharmacokinetics of goserelin.
Cockshott ID. Cockshott ID. Clin Pharmacokinet. 2000 Jul;39(1):27-48. doi: 10.2165/00003088-200039010-00003. Clin Pharmacokinet. 2000. PMID: 10926349 Review.
Goserelin is a synthetic decapeptide analogue of luteinising hormone-releasing hormone (LHRH). ...There is no clinically relevant accumulation of goserelin during multiple administration of these depots. Goserelin is extensively metabolised prior to excretion …
Goserelin is a synthetic decapeptide analogue of luteinising hormone-releasing hormone (LHRH). ...There is no clinically relevant acc …
Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.
Cheer SM, Plosker GL, Simpson D, Wagstaff AJ. Cheer SM, et al. Drugs. 2005;65(18):2639-55. doi: 10.2165/00003495-200565180-00011. Drugs. 2005. PMID: 16392882 Review.
Furthermore, the addition of goserelin to adjuvant chemotherapy appeared to offer an advantage over chemotherapy alone in younger patients. Fewer patients remained amenorrheic after goserelin therapy than after chemotherapy. Complete endocrine blockade provided by t …
Furthermore, the addition of goserelin to adjuvant chemotherapy appeared to offer an advantage over chemotherapy alone in younger pat …
Erythema nodosum caused by goserelin acetate sustained-release: Case report and literature review.
Meng F, Su R, Ling L, Yan W, Du S, Peng J, Liu W. Meng F, et al. Int J Rheum Dis. 2023 Oct;26(10):2055-2059. doi: 10.1111/1756-185X.14692. Epub 2023 Apr 28. Int J Rheum Dis. 2023. PMID: 37114900 Review.
Goserelin acetate is a gonadotropin-releasing hormone analog that is commonly used in patients with prostate cancer, endometriosis, and precocious puberty. ...In this paper, we have presented the case of erythema nodosum caused by goserelin acetate and a review of t …
Goserelin acetate is a gonadotropin-releasing hormone analog that is commonly used in patients with prostate cancer, endometriosis, a …
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.
Brogden RN, Faulds D. Brogden RN, et al. Drugs Aging. 1995 Apr;6(4):324-43. doi: 10.2165/00002512-199506040-00007. Drugs Aging. 1995. PMID: 7613021 Review.
Goserelin is administered subcutaneously as a biodegradable depot formulation incorporating 3.6mg of the drug, which is released continuously over 4 weeks. ...Goserelin is better tolerated than diethylstilbestrol and appears to have a more favourable effect on quali …
Goserelin is administered subcutaneously as a biodegradable depot formulation incorporating 3.6mg of the drug, which is released cont …
Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.
Gu C, Wang Z, Lin T, Liu Z, Han W, Zhang X, Liang C, Liu H, Yu Y, Xu Z, Liu S, Wang J, Jia L, Yao X, Liao W, Fu C, Tan Z, He G, Zhu G, Fan R, Yang W, Chen X, Liu Z, Zhong L, Shi B, Ding D, Chen S, Wei J, Yao X, Chen M, Lu Z, Xie Q, Hu Z, Wang Y, Guo H, Fan T, Liang Z, Chen P, Wang W, Xu T, Li C, Xing J, Liao H, He D, Wu Z, Yu J, Feng Z, Yang M, Dou Q, Zeng Q, Li Y, Gou X, Zhou G, Wang X, Zhu R, Zhang Z, Zhang B, Tan W, Qu X, Sun H, Gan T, Ye D. Gu C, et al. Chin Med J (Engl). 2023 May 20;136(10):1207-1215. doi: 10.1097/CM9.0000000000002638. Epub 2023 Apr 3. Chin Med J (Engl). 2023. PMID: 37010251 Free PMC article. Clinical Trial.
BACKGROUND: LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) agonist injected monthly. ...LY01005 was associated with fewer injection-site reactions than the goserelin implant (0% vs . 1.4% [2/14 …
BACKGROUND: LY01005 (Goserelin acetate sustained-release microsphere injection) is a modified gonadotropin-releasing hormone (GnRH) a …
Goserelin acetate in combination with radiotherapy for prostate cancer.
Roach M 3rd, Izaguirre A. Roach M 3rd, et al. Expert Opin Pharmacother. 2007 Feb;8(2):257-64. doi: 10.1517/14656566.8.2.257. Expert Opin Pharmacother. 2007. PMID: 17257094 Review.
In these studies, ADT was administered in the form of surgery (orchiectomy) or with a class of drugs called luteinizing hormone-releasing hormone agonists. Goserelin acetate is a member of this class, and 10 of 11 major Phase III trials demonstrating better outcomes with A …
In these studies, ADT was administered in the form of surgery (orchiectomy) or with a class of drugs called luteinizing hormone-releasing ho …
Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women.
Jonat W. Jonat W. Br J Cancer. 2001 Nov;85 Suppl 2(Suppl 2):1-5. doi: 10.1054/bjoc.2001.1981. Br J Cancer. 2001. PMID: 11900209 Free PMC article. Review.
The use of goserelin in the management of early breast cancer presents an option which can avoid the side-effects experienced with cytotoxic chemotherapy and may offer unique benefits to premenopausal patients. The consolidation of these emerging results should help in def …
The use of goserelin in the management of early breast cancer presents an option which can avoid the side-effects experienced with cy …
2,029 results